Latest Commercial Sales News

Neuren has lifted its 2026 trofinetide income guidance to US$91 million-US$93 million after Acadia reported a 39% rise in Q3 DAYBUE sales and a US$35 million German launch milestone. Japan trial results also support a planned 2027 regulatory filing, although a launch remains subject to approval and a distribution partner.

Palantir delivered a record fiscal third quarter, with revenue rising 96% to US$2.313 billion and US commercial revenue overtaking government revenue for the first time. The company also lifted its full-year 2026 guidance across revenue, commercial sales and cash flow.

Alpha HPA has moved closer to commissioning its flagship Stage 2 facility, with permanent plant energisation targeted for December while Stage 1 customer demand continues to outstrip available capacity. The company also began drawing funds from a $160 million government-backed commitment and reported $81.4 million in cash at quarter-end.

ClearVue Technologies has converted its Canva project into a binding subcontract and secured certifications that broaden the market for its solar glass. But the ASX-listed company ended Q1 FY27 with A$2.281 million in cash, A$2.666 million of quarterly operating outflows and estimated funding for just 1.3 quarters.

xReality Group expanded its Operator XR customer base, recurring revenue and sales pipeline in the first quarter, while securing its first US Marine Corps order after quarter end. But the company remains focused on completing its FY26 audit and reinstating trading, with $1.4 million in quarter-end cash against $4.55 million of secured debt.

Sparc Technologies has moved its graphene additive business from testing towards commercial adoption, with a first ecosparc® delivery to a tier 1 coatings manufacturer and more than 20 active qualification programs. The September quarter also delivered hydrogen progress and fresh funding, but the company reported only 1.14 quarters of cash coverage before subsequent receipts.

Hydrix reported September-quarter revenue growth of 11.6% year on year and secured further medical and Defence milestones. But with $1.5 million in cash and reported funding covering only 1.30 quarters, the company still needs contract wins to convert into receipts and revenue.

Antimony Resources says its Tecomatlán processing plant in Mexico has entered the concentrate production phase, with key circuits operational and a first bulk antimony concentrate now targeted. The result remains unverified: the company still needs to demonstrate stable recoveries, confirm product quality and complete a commercial sale.

Cobalt Blue has moved closer to a commercial pathway for its Kwinana refinery with a non-binding cobalt metal offtake term sheet, while studies across its project portfolio gather pace. The September quarter also left the company with A$2.852 million in cash, equivalent to 2.24 quarters of estimated funding at the reported burn rate.

Minbos Resources has extracted its first phosphate rock from the Cacata deposit in Angola, stockpiling material ahead of November rains and planned Subantando plant commissioning in Q2 2027. The milestone marks operational progress, although assay results, commercial approvals and tenement formalisation remain outstanding.

Syrah Resources delivered a stronger Balama quarter and began ramping Vidalia’s US anode-material facility towards commercial sales. But higher cost guidance, negative operating cash flow and unresolved loan defaults leave the balance sheet as the central risk.

The Australian Takeovers Panel has declared unacceptable circumstances in A2MP Investments’ lapsed A$0.05-a-share takeover bid for Canyon Resources, citing inadequate disclosure, the use of confidential information and potential coercion of shareholders. Final orders remain undecided.